{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:01:19Z","timestamp":1770753679460,"version":"3.50.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau-IIB Sant Pau"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","ijdp.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.drugpo.2018.06.007","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T12:06:00Z","timestamp":1530014760000},"page":"126-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Development and validation of the scale to assess satisfaction with medications for addiction treatment \u2013 Buprenorphine-naloxone for heroin addiction (SASMAT-BUNHER)"],"prefix":"10.1016","volume":"58","author":[{"given":"Jos\u00e9","family":"P\u00e9rez de los Cobos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Trujols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5720-8801","authenticated-orcid":false,"given":"Saul","family":"Alcaraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Si\u00f1ol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d3scar","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Gonz\u00e1lez-Saiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugpo.2018.06.007_bib0005","first-page":"893","article-title":"Instruments to assess patient satisfaction after teleconsultation and triage: A systematic review","volume":"8","author":"Allemann Iseli","year":"2014","journal-title":"Patient Preference and Adherence"},{"issue":"Suppl. 1","key":"10.1016\/j.drugpo.2018.06.007_bib0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/11536060-000000000-00000","article-title":"Clinical experience with fortnightly buprenorphine\/naloxone versus buprenorphine in Italy","volume":"30","author":"Amato","year":"2010","journal-title":"Clinical Drug Investigation"},{"key":"10.1016\/j.drugpo.2018.06.007_bib0015","series-title":"Diagnostic and statistical manual of mental disorders: DSM-IV","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.drugpo.2018.06.007_bib0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health and Quality of Life Outcomes"},{"issue":"2","key":"10.1016\/j.drugpo.2018.06.007_bib0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1207\/s15327906mbr0102_10","article-title":"The scree test for the number of factors","volume":"1","author":"Cattell","year":"1966","journal-title":"Multivariate Behavioral Research"},{"issue":"4","key":"10.1016\/j.drugpo.2018.06.007_bib0030","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1037\/1040-3590.6.4.284","article-title":"Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology","volume":"6","author":"Cicchetti","year":"1994","journal-title":"Psychological Assessment"},{"issue":"3","key":"10.1016\/j.drugpo.2018.06.007_bib0035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF02310555","article-title":"Coefficient alpha and the internal structure of tests","volume":"16","author":"Cronbach","year":"1951","journal-title":"Psychometrika"},{"issue":"32","key":"10.1016\/j.drugpo.2018.06.007_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6320","article-title":"The measurement of satisfaction with healthcare: Implications for practice from a systematic review of the literature","volume":"6","author":"Crow","year":"2002","journal-title":"Health Technology Assessment"},{"issue":"1","key":"10.1016\/j.drugpo.2018.06.007_bib0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jsat.2009.07.002","article-title":"Preference for buprenorphine\/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: A prospective, multicenter study","volume":"38","author":"Daulou\u00e8de","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"349","key":"10.1016\/j.drugpo.2018.06.007_bib0050","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","author":"Fudala","year":"2003","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.drugpo.2018.06.007_bib0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF02289447","article-title":"A rationale and test for the number of factors in factor analysis","volume":"30","author":"Horn","year":"1965","journal-title":"Psychometrika"},{"key":"10.1016\/j.drugpo.2018.06.007_bib0060","series-title":"The ITC guidelines for translating and adapting tests","author":"International Test Commission","year":"2017"},{"issue":"1","key":"10.1016\/j.drugpo.2018.06.007_bib0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0376-8716(95)01186-2","article-title":"A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence","volume":"40","author":"Johnson","year":"1995","journal-title":"Drug and Alcohol Dependence"},{"issue":"2 (Suppl)","key":"10.1016\/j.drugpo.2018.06.007_bib0070","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: How to use it right","volume":"70","author":"Johnson","year":"2003","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.drugpo.2018.06.007_bib0075","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.biopsych.2007.05.001","article-title":"Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence","volume":"63","author":"Kakko","year":"2008","journal-title":"Biological Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.drugpo.2018.06.007_bib0080","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0024-3205(83)90529-5","article-title":"Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans","volume":"33","author":"Kreek","year":"1983","journal-title":"Life Sciences"},{"issue":"3","key":"10.1016\/j.drugpo.2018.06.007_bib0085","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3758\/BRM.42.3.871","article-title":"Estimating confidence intervals for eigenvalues in exploratory factor analysis","volume":"42","author":"Larsen","year":"2010","journal-title":"Behavior Research Methods"},{"issue":"4","key":"10.1016\/j.drugpo.2018.06.007_bib0090","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","article-title":"Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial","volume":"93","author":"Ling","year":"1998","journal-title":"Addiction"},{"issue":"1\u20133","key":"10.1016\/j.drugpo.2018.06.007_bib0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.drugalcdep.2012.12.009","article-title":"A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence","volume":"131","author":"Lintzeris","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.drugpo.2018.06.007_bib0100","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1016\/j.drugpo.2018.06.007_bib0105","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/1475-6773.11194","article-title":"A demonstration of the impact of response bias on the results of patient satisfaction surveys","volume":"37","author":"Mazor","year":"2002","journal-title":"Health Services Research"},{"issue":"Suppl. 1","key":"10.1016\/j.drugpo.2018.06.007_bib0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/11536040-000000000-00000","article-title":"Therapeutic switch to buprenorphine\/naloxone from buprenorphine alone: Clinical experience in an Italian addiction centre","volume":"30","author":"Montesano","year":"2010","journal-title":"Clinical Drug Investigation"},{"issue":"1","key":"10.1016\/j.drugpo.2018.06.007_bib0115","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clpt.2003.09.004","article-title":"Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence","volume":"75","author":"Montoya","year":"2004","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.drugpo.2018.06.007_bib0120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.7334\/psicothema2013.24","article-title":"International test commission guidelines for test translation and adaptation: Second edition","volume":"25","author":"Mu\u00f1iz","year":"2013","journal-title":"Psicothema"},{"issue":"5","key":"10.1016\/j.drugpo.2018.06.007_bib0125","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.pnpbp.2007.03.013","article-title":"Chronic cannabis use does not affect the normalization of hypothalamic-pituitary-adrenal (HPA) axis induced by methadone in heroin addicts","volume":"31","author":"Nava","year":"2007","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.drugpo.2018.06.007_bib0130","series-title":"Psychometric theory","author":"Nunnally","year":"1994"},{"key":"10.1016\/j.drugpo.2018.06.007_bib0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.drugalcdep.2014.05.024","article-title":"Development and validation of the scale to assess satisfaction with medications for addiction treatment-methadone for heroin addiction (SASMAT-METHER)","volume":"142","author":"P\u00e9rez de los Cobos","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.drugpo.2018.06.007_bib0140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/JCP.0000000000000463","article-title":"Satisfaction with methadone among heroin-dependent patients with current substance use disorders during methadone maintenance treatment","volume":"36","author":"P\u00e9rez de los Cobos","year":"2016","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"6","key":"10.1016\/j.drugpo.2018.06.007_bib0145","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF00802049","article-title":"Acceptability, sensitivity and content validity of the VECS and VSSS in measuring expectations and satisfaction in psychiatric patients and their relatives","volume":"29","author":"Ruggeri","year":"1994","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"issue":"2","key":"10.1016\/j.drugpo.2018.06.007_bib0150","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1524-4733.2004.72252.x","article-title":"Satisfaction with medication: An overview of conceptual, methodologic, and regulatory issues","volume":"7","author":"Shikiar","year":"2004","journal-title":"Value in Health"},{"issue":"12","key":"10.1016\/j.drugpo.2018.06.007_bib0155","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0277-9536(97)00128-7","article-title":"Patient satisfaction: A review of issues and concepts","volume":"45","author":"Sitzia","year":"1997","journal-title":"Social Science & Medicine"},{"key":"10.1016\/j.drugpo.2018.06.007_bib0160","series-title":"Understanding health care outcomes research","first-page":"185","article-title":"Satisfaction with care","author":"Smith","year":"2006"},{"issue":"Suppl. 1","key":"10.1016\/j.drugpo.2018.06.007_bib0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/11536030-000000000-00000","article-title":"Safety and tolerability of the switch from buprenorphine to buprenorphine\/naloxone in an Italian addiction treatment centre","volume":"30","author":"Stimolo","year":"2010","journal-title":"Clinical Drug Investigation"},{"issue":"1","key":"10.1016\/j.drugpo.2018.06.007_bib0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7326\/0003-4819-119-1-199307010-00004","article-title":"Dose-response effects of methadone in the treatment of opioid dependence","volume":"119","author":"Strain","year":"1993","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.drugpo.2018.06.007_bib0175","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1524-4733.2005.04054.x","article-title":"Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR task force for translation and cultural adaptation","volume":"8","author":"Wild","year":"2005","journal-title":"Value in Health"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395918301695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395918301695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T10:05:12Z","timestamp":1751709912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395918301695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":35,"alternative-id":["S0955395918301695"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2018.06.007","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of the scale to assess satisfaction with medications for addiction treatment \u2013 Buprenorphine-naloxone for heroin addiction (SASMAT-BUNHER)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2018.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}